Metformin Legal & Patent Challenges: FDA Approval, Label History, and Safety Oversight

When Was Metformin FDA Approved and What Was the Patent Situation?

Metformin hydrochloride was approved by the FDA on December 29, 1994, under NDA 020357, marketed as Glucophage by Bristol-Myers Squibb. The core compound patent had already expired in Europe years earlier, metformin was first approved in the UK in 1958, but U.S. Exclusivity allowed BMS to hold branded market share through 2002. Once that exclusivity lapsed, more than 40 abbreviated new drug applications (ANDAs) were approved, and the branded product's market share collapsed within 18 months.

The 1994 NDA and Data Package

Bristol-Myers Squibb submitted a clinical package anchored heavily in European data accumulated over three decades. The FDA required additional U.S.-based trials before granting approval. The agency's clinical review highlighted the biguanide class's mechanism, inhibition of hepatic glucose production via AMPK activation, and flagged lactic acidosis risk as the principal safety signal requiring a boxed warning. That boxed warning remains on every metformin label today. The full approval history is searchable at FDA Drugs@FDA.

Patent Expiry and the Generic Market

The primary composition-of-matter patent for metformin HCl (U.S. Patent 3,174,901) had long since expired by the time U.S. Approval was granted. BMS held market exclusivity through formulation and method-of-use patents rather than a compound patent. Those protections ended around 2002. FDA's Orange Book now lists more than 40 approved ANDA holders for immediate-release metformin and more than a dozen for extended-release formulations.

What Does the Current Metformin FDA Label Say?

The current prescribing information covers four areas that have changed substantially since 1994: the boxed warning for lactic acidosis, the 2016 renal dosing revision, the pediatric indication added in 2000, and the 2020 NDMA-related extended-release labeling actions.

Boxed Warning: Lactic Acidosis

The boxed warning, present since the original 1994 label, states that lactic acidosis is a rare but serious metabolic complication. The FDA estimates incidence at approximately 3 cases per 100,000 patient-years, with a case fatality rate of roughly 50% in reported cases. The current FDA-approved label is available at DailyMed. Risk factors listed include renal impairment, hepatic impairment, congestive heart failure, and alcohol use. The label instructs clinicians to withhold metformin in patients undergoing iodinated contrast procedures based on eGFR thresholds established in the 2016 revision.

The 2016 Renal Dosing Revision

Before 2016, the FDA label contraindicated metformin in any patient with a serum creatinine at or above 1.5 mg/dL in men or 1.4 mg/dL in women. Those cutoffs were criticized widely because they excluded many patients with adequate kidney function, particularly older women with lower muscle mass. In April 2016, FDA revised the label to use estimated glomerular filtration rate (eGFR) instead. The updated guidance:

• Contraindicates initiation when eGFR is <30 mL/min/1.73 m²
• Recommends against initiating when eGFR is 30 to 45 mL/min/1.73 m²
• Allows continued use with monitoring when eGFR falls between 30 and 45 in patients already established on therapy

This change aligned U.S. Labeling with the European Medicines Agency position and with guidance from the National Kidney Foundation. The FDA safety communication announcing this revision is available here.

Pediatric Indication

The FDA granted a pediatric indication for metformin in children aged 10 and older in 2000, based on a clinical trial showing glycemic efficacy in adolescents with type 2 diabetes. No separate ANDA pathway was needed; existing manufacturers updated their labels. The American Diabetes Association's Standards of Care reinforce this indication. ADA Standards of Medical Care in Diabetes 2024 are available at diabetesjournals.org.

The 2020 NDMA Contamination Crisis: What Happened and How Was It Resolved?

N-nitrosodimethylamine (NDMA) contamination, first identified in ranitidine and sartan-class antihypertensives, extended to certain extended-release metformin formulations in 2020. The FDA's response followed a defined post-market surveillance pathway and led to the largest voluntary recall action in the drug's U.S. History.

How the FDA Detected the Problem

In May 2020, FDA announced it had found NDMA levels above the acceptable daily intake (ADI) threshold of 96 nanograms per day in some extended-release metformin products. The original FDA announcement is archived here. The agency used its own laboratory testing rather than relying solely on manufacturer submissions, reflecting an increased role for the FDA Sentinel System and the agency's Pharmaceutical Quality database in proactive surveillance.

Which Manufacturers Recalled Products

Between May and September 2020, at least five manufacturers issued voluntary recalls of specific extended-release lots:

• Amneal Pharmaceuticals recalled multiple lot numbers of metformin HCl extended-release 500 mg and 750 mg tablets.
• Apotex Corp recalled certain 500 mg extended-release lots.
• Marksans Pharma recalled extended-release lots distributed under several store-brand labels.
• Bayshore Pharmaceuticals and AvKARE issued parallel voluntary recalls.

FDA's recall database entries for these actions are searchable at FDA Recalls, Market Withdrawals, and Safety Alerts.

Immediate-release metformin formulations were not recalled. No NDMA contamination above the ADI was detected in immediate-release products.

Resolution and Ongoing Testing Requirements

By late 2020, FDA had tested products from all major metformin manufacturers. The agency did not mandate a class-wide recall of extended-release formulations. Instead, it issued guidance requiring manufacturers to test finished product lots for NDMA before distribution if testing indicated a risk. Manufacturers whose products tested below the 96 ng/day ADI were permitted to continue distribution. The FDA guidance document on nitrosamine impurities in drug products is available here.

Key Clinical Evidence Supporting Metformin's Regulatory Standing

Metformin's durable place on formularies globally rests on a trial evidence base that predates most modern GLP-1 receptor agonist data. Two trials are central to every regulatory and clinical discussion.

UKPDS 34: The Foundational Efficacy and Mortality Trial

The UK Prospective Diabetes Study 34 (UKPDS 34, N=1,704) randomized overweight patients with newly diagnosed type 2 diabetes to intensive glucose control with metformin versus conventional diet-based management. Over a median follow-up of 10.7 years, metformin-allocated patients showed a 32% reduction in any diabetes-related endpoint (P<0.002), a 42% reduction in diabetes-related death (P<0.017), and a 36% reduction in all-cause mortality (P<0.011) compared with conventional therapy. UKPDS 34, Lancet 1998; PMID 9742976.

These mortality data are unique among oral antidiabetic agents approved in the 1990s and remain the primary reason metformin appears as first-line therapy in virtually every major guideline. As the ADA's Standards of Medical Care state: "Metformin, if tolerated and not contraindicated, is the preferred initial pharmacologic agent for the treatment of type 2 diabetes." ADA Standards of Care 2024, diabetesjournals.org.

Diabetes Prevention Program: Expanded Regulatory Context

The Diabetes Prevention Program (DPP, N=3,234) found that metformin 850 mg twice daily reduced progression from prediabetes to type 2 diabetes by 31% over 2.8 years (P<0.001) compared with placebo. DPP Research Group, NEJM 2002; PMID 11832527. Metformin does not carry an FDA-approved indication for diabetes prevention, but the DPP data underpin off-label use that the ADA formally supports in its guidelines for high-risk individuals.

FDA Sentinel System and Post-Market Surveillance of Metformin

The FDA Sentinel System, a distributed post-market surveillance network covering more than 100 million patient records, has evaluated metformin safety signals on multiple occasions since its launch in 2008.

Lactic Acidosis Signal Monitoring

Early Sentinel analyses confirmed that the real-world incidence of lactic acidosis in metformin users is substantially lower than estimates from older case series, supporting the 2016 label revision. FDA Sentinel System overview and published analyses are available at FDA.gov. A 2015 meta-analysis in Cochrane Database (Salpeter et al., updated by Diabetes Care publications) found no statistically significant increase in lactic acidosis incidence in patients with renal impairment using metformin compared with those on other antidiabetic therapies, provided eGFR remained above 30 mL/min/1.73 m². Cochrane review on metformin and lactic acidosis.

Cardiovascular Signal Assessment

Post-DPP follow-up data (DPPOS, 15-year outcomes) and multiple observational studies fed into FDA Sentinel queries examining whether metformin carries cardiovascular benefit in non-diabetic populations. DPPOS 15-year outcomes, Lancet Diabetes Endocrinol 2015; PMID 26377054. The FDA has not approved a cardiovascular indication, but the absence of a cardiovascular harm signal has reinforced the drug's safety profile in labeling discussions.

Vitamin B12 Deficiency Monitoring

Since 2016, the metformin label has included a recommendation for periodic monitoring of vitamin B12 levels in long-term users. Sentinel and observational data showed that approximately 7% of metformin users develop biochemically low B12 after 4 years of continuous use, rising to nearly 20% after 10 years in some cohort analyses. NEJM 2012 DPPOS B12 substudy; PMID 22630086. The label now reads: "Measurement of hematologic parameters on an annual basis is advised in patients on long-term treatment and any apparent abnormalities should be investigated and managed."

Are There Active Legal or Patent Disputes Involving Metformin?

No active composition-of-matter patent litigation involves metformin as of 2025. The compound has been off-patent in the U.S. For more than two decades.

Historical Paragraph IV Certifications

Between 2002 and 2008, several ANDA applicants filed Paragraph IV certifications challenging BMS's extended-release Glucophage XR formulation patents. At least three U.S. District court cases resolved in favor of the generic challengers, accelerating generic entry for the extended-release formulation. Those cases are now largely moot given the complete expiry of all relevant formulation patents.

Litigation Arising from NDMA Recalls

The 2020 NDMA recalls triggered product liability litigation in multiple U.S. Federal courts. Plaintiffs alleged injury from NDMA exposure in extended-release lots. As of early 2025, most cases have been consolidated in multi-district litigation proceedings, but no major jury verdicts have been published. Manufacturers have generally contested causation claims given the low absolute NDMA levels involved and the absence of an established NDMA dose-response threshold for harm at the concentrations detected.

Compounding Pharmacy Legal Tension

A separate but related regulatory tension involves compounded metformin products, particularly in combination with other agents such as semaglutide or NAD precursors. FDA's 503A and 503B compounding frameworks do not list metformin as a compound in shortage or on the FDA drug shortage list, which limits compounders' legal authority to produce bulk-metformin compounds for commercial distribution. FDA's current drug shortage list is searchable at FDA.gov. Clinicians prescribing compounded metformin combinations should verify that the compounder holds appropriate 503B outsourcing facility registration.

EMA and International Regulatory Alignment

The European Medicines Agency's EPAR (European Public Assessment Report) for metformin-containing products tracks closely with FDA labeling on lactic acidosis risk and renal thresholds. The EMA's eGFR cutoff for contraindication matches the FDA's 30 mL/min/1.73 m² threshold, a convergence that followed parallel scientific reviews in 2014 and 2016. EMA product information for metformin is available at the EMA website.

The World Health Organization lists metformin on its Model List of Essential Medicines. WHO Model List of Essential Medicines, 23rd edition. That designation carries no patent implications but does support procurement programs in low- and middle-income countries, where generic pricing for metformin has reached below $0.01 per tablet in some tender markets.

What Clinicians Need to Know: Practical Regulatory Implications

Regulatory changes translate into specific clinical actions. The table below summarizes the label provisions most relevant to prescribing decisions.

| Regulatory Action | Year | Clinical Impact | |---|---|---| | Original FDA approval, NDA 020357 | 1994 | Metformin HCl available in the U.S. | | Pediatric indication added | 2000 | Approved for type 2 diabetes, age 10 and older | | Generic entry (ANDA approvals) | 2002 onward | Cost reduction; more than 40 generics | | eGFR-based renal dosing revision | 2016 | Contraindicated at eGFR <30; start with caution 30-45 | | B12 monitoring added to label | 2016 | Annual B12 check recommended for long-term users | | NDMA extended-release recalls | 2020 | Certain ER lots recalled; IR formulations unaffected | | Nitrosamine testing guidance | 2020-2021 | Manufacturers must test lots before distribution |

The 2016 renal revision is the single most clinically significant label change in metformin's U.S. History. Before that revision, an estimated 1.5 million U.S. Patients were withheld metformin unnecessarily based on the obsolete serum-creatinine thresholds. Clinicians who trained before 2016 should confirm their dosing practice reflects the current eGFR-based standard.

For extended-release prescribing specifically: patients currently taking ER metformin whose specific lot was recalled in 2020 should have been transitioned to unaffected lots or immediate-release formulations at that time. No ongoing lot-level restrictions apply to currently distributed ER metformin products that have passed NDMA testing.

The B12 depletion signal is low-grade but cumulative. A baseline B12 level before initiating long-term metformin, followed by annual checks, costs less than $20 in most U.S. Laboratory settings and can prevent a preventable peripheral neuropathy diagnosis. Check eGFR at baseline and at least annually in all metformin users; dose accordingly using the thresholds in the current FDA label.